SCHEMBL28731637

SCHEMBL28731637

Cn1nc2cnc(Br)cc2c1I

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14912717 0.80 CHRM4 (0.36) —
SCHEMBL28731684 0.77 ADORA3 (0.32) —
SCHEMBL22650538 0.73 — —
SCHEMBL21114102 0.69 HRH4 (0.37) —
SCHEMBL31211037 0.68 PDE10A (0.36) —
SCHEMBL31419475 0.68 ADORA2A (0.37) —
SCHEMBL22650529 0.66 PIM1 (0.34) —
SCHEMBL24121824 0.66 CHRM4 (0.36) —
SCHEMBL14912061 0.66 ADORA2A (0.57) —
SCHEMBL21265906 0.66 MEN1 (0.37) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120040446-A CDK inhibitors 基因泰克公司 2025-05-27 — — CN disclosed
US-20220296595-A1 CDK INHIBITORS GENENTECH, INC. 2022-09-22 — — US disclosed
CN-114364675-A CDK inhibitors 上海齐鲁锐格医药研发有限公司 2022-04-15 — — CN disclosed
EP-3966213-A1 CDK INHIBITORS Qilu Regor Therapeutics Inc. (CN) 2022-03-16 — — EP disclosed
Send feedback